Archive for the 'Trends' Category

Future Hub of Biotech: Boston or San Francisco?

San Francisco and Boston sit on opposite coasts and each has a rich history and character that make them distinct. However, they share some similarities: both cities are centers of top biotechnology hubs in the US. Read more »

Social Media and the Pharma Industry

PharmTech’s February issue will feature a guest editorial by Aaron Davidson, a partner in the life sciences practice at Baker Botts, on social media and the pharmaceutical industry. In his editorial, Mr. Davidson points to FDA and a lack of regulatory guidance as the reasons that social media has not caught on in the pharma and bio/pharma industries. FDA’s requirement to provide consumers with FDA-approved promotional materials that contain risk information may limit a pharmaceutical company’s ability to use mediums such as Twitter and Facebook effectively.

Read more »

Pharma’s Reputation in Decline

Stephanie Sutton Pharm Tech EuropeThe pharmaceutical industry does not have a good reputation among patients and consumers.

This may seem like an unfair situation given the fact that medicines produced by the pharmaceutical industry save millions of lives each year, but humans are far better at focusing on the bad things than the good, and recent recalls, controversial pricing policies and lawsuits have definitely given people reason to focus on the negative side of the pharmaceutical industry. Read more »

Big Pharma’s Shrinking Firepower for M&A Deals

Over the last two years, the gap between analysts’ estimates of big pharma sales and the global drug market forecast by IMS Health has widened significantly. In 2011, the overall drug market saw growth that overtook big pharma by approximately $20 billion; it is anticipated that this gap will further widen to $50 billion in 2012 because of major brands falling off the patent cliff. Read more »

When Will Pharmacogenomics Live up to its Promise?

Stephanie Sutton Pharm Tech EuropeIn about 20 years and with a cost of around $10 billion. That’s the estimate given by researchers at the Beth Israel Deaconess Medical Center in the US who used quantitative modelling to forecast how much time and money would be required before pharmacogenomics could be expected to be used in clinical care. Read more »

A New Year in Pharma

A new year has started in the world of pharmaceutical manufacturing and technology, and 2013 looks to bring plenty of innovation. PharmTech’s January issue highlights what the pharma industry can expect in the upcoming year.

Look for a discussion with FDA on the changing scope of regulatory science and its effect on drug reviews, site inspections, and approvals as well as academia’s role in the future of pharmaceutical manufacturing. We will also have a look at the future of CMOs and ISPE’s view on the future of the quality laboratory.

We would also like to know what you think the new year will bring! Please leave your comments on what your company’s goals and innovative projects are for the new year, and be sure to let us know what you would like to see us cover in the year to come!

Sanofi Campaign Targets Counterfeit Medicines

Stephanie Sutton Pharm Tech EuropePassengers travelling via Air France this December will see an in-cabin movie made by Sanofi to raise awareness about the dangers of counterfeit drugs.

According to Sanofi’s video, up to 10% of the world’s medicines can be counterfeit. In industrialised countries, counterfeit medicines are rare and many patients and consumers may not be fully aware of the dangers. In other locations, however, such as some countries in Africa, Asia, Latin America and in emerging markets, counterfeit medicines may comprise 20–30% of the market. Travellers are not always aware of the risk when venturing to another country. Read more »

Personalised Medicine: Pharma’s Golden Era?

Stephanie Sutton Pharm Tech EuropeA golden era of productivity awaits the pharmaceutical industry in 2020, according to a report from PricewaterhouseCoopers (PwC). In an industry that seems to be dominated by headlines of job cuts and low growth, it’s a relief to hear positive news that suggests there’s light at the end of the tunnel. Read more »

Towards Greater Transparency of Clinical Trials Data

As an industry that is constantly being scrutinised, pharma is now under pressure to openly publish all data from clinical trials, including negative results such as failures of medicines during phase I–III evaluation. From January onwards, the British Medical Journal (BMJ) will only publish studies on drugs and devices, whether industry funded or not, where there is a commitment to “make the relevant anonymised patient level data available on reasonable request.” The move was fully supported by GlaxoSmithKline (GSK), who is already posting results from all its clinical trials on the company’s website. In a press release, Patrick Vallance, the president of pharmaceuticals R&D at GSK, said, “Moves like this should help medical research by allowing scientists to study the detailed results of clinical trials and increase understanding of current and new medicines.” Read more »

When Disaster Strikes at Home

Angie DrakulichThe editorial offices of PharmTech are based in New Jersey, so when Hurricane Sandy hit last month, we were all affected. Flooding and high winds destroyed many coastline homes along with well-known destinations across Atlantic City, the Jersey Shore, and the neighboring Manhattan boroughs. Suburban communities and businesses (including many US biopharma manufacturing headquarters) across the state were without power for days and schools were shutdown for a week or more in several counties. President Obama declared the state, along with New York, a major disaster area. The entire ordeal was quite surreal, and our team considers ourselves to be lucky that we made it through unscathed. Our thoughts go out to those who are still recovering from the storm and trying to get back to normal. Read more »

« Previous PageNext Page »